Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700422 · ClinicalTrials.gov registry record · Phase 4
Nasal Spray Study in Sjogren's Dry Eye Disease
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
NCT05700422: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT05700422 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05700422, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month. You will also self-administer the nasal spray at home every day, 2 times a day during this month.
Interventions
- DRUG Varenicline Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700422
The ClinicalTrials.gov registry entry for NCT05700422 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varenicline Nasal Spray is the first listed.
NCT05700422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05700422 about?
NCT05700422 is a clinical study titled "Nasal Spray Study in Sjogren's Dry Eye Disease". This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in...
What is the current status of trial NCT05700422?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2023-05-01. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05700422?
The interventions under investigation include: Varenicline Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT05700422?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.